die

Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies

The Epstein Barr virus (EBV), which causes infectious mononucleosis (IM), is one of the most common human viruses. EBV occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95 percent of adults between 35 and 40 years of age have been infected. In most developed countries, including the U.S., infection with EBV most often occu...

Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

- Results Fail to Demonstrate Meaningful Placebo Adjusted WeightLoss; Obesity Program to be Discontinued NEW YORK, July 09, 2007 /PRNewswire-FirstCall/ -- ManhattanPharmaceuticals, Inc. today announced results of the company's twoPhase 2a clinical trials of oral Oleoyl-estrone (OE). The resultsof both randomized, double-blind, placebo-controlled studies, onein common obesity and the other...

NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc.(NASDAQ: NEXM), a developer of innovative transdermal treatmentsbased on the NexACT(R) drug delivery technology, today announcedthat Novartis Pharma AG has completed patient enrollment for PhaseIII clinical trials for NM100060, a topical treatment foronychomycosis (nail fungus). Pursuant to the terms of the licensingagreement w...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers

WASHINGTON, January 29, 2007 /PRNewswire-USNewswire/ -- RearAdmiral Timothy Ziemer (U.S. Navy, retired), the President'sMalaria Coordinator, announced his intent to name Dr. BernardNahlen to serve as Deputy Coordinator of the President's MalariaInitiative (PMI). Dr. Nahlen is a Commissioned Officer in the U.S.Public Heath Service and has most recently served as SeniorAdvisor, Monitoring...

Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythe results from two Phase II non-randomized studies of seliciclibfixed dose combinations. In one study seliciclib was given incombination with gemcitabine and cisplatin and in another withdocetaxel in patients with advanced non-small cell lung cancer(NSCLC).<p...

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated(Nasdaq:INSM), a biopharmaceutical company focused on thedevelopment and approval of drugs for the treatment of metabolicdiseases with unmet medical needs, today noted the publication ofpromising results of research from three universities regarding thepotential role of insulin-like growth factor binding protein-3(IGFBP-3) in...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

Eurand's Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show

Zentase Improves Absorption of Fat, Protein and Other Nutrients inPatients with Mild, Moderate or Severe Malabsorption, WhileControlling Symptoms of Exocrine Pancreatic Insufficiency MILAN, Italy and DAYTON, Ohio, June 19, 2007/PRNewswire-FirstCall/ -- Eurand N.V. today announced results thatwere presented at the recent European Cystic Fibrosis Societymeeting in Antalya, Turkey, held June...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced that data from previousPhase 1 and Phase 2a clinical studies for NG2-73, the Company'slead compound for the treatment of insomnia, were presented in twosessions at the SLEEP 2007 Annual Meeting of the AssociatedProfessional Sleep Societies (APSS) in Minneapolis, Minnesota. TwoPhase 2b clinica...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

Data Highlights the Impact of Insomnia on Healthcare System andWorker Productivity SAN DIEGO, June 12, 2007 /PRNewswire-FirstCall/ -- NeurocrineBiosciences, Inc. announced today that results from severalresearch studies on the impact of chronic primary and transientinsomnia were presented this week at the Associated ProfessionalSleep Societies (APSS) Annual Meeting. APSS highlights show t...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates, SNS-595 and SNS-032, at the 12thCongress of the European Hematology Association (E...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

- Data presented at 12th Congress of European Hematology - CHESHIRE, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- AlexionPharmaceuticals, Inc. today announced results from three analysesof Phase III studies examining Soliris(TM) (eculizumab) for thetreatment of paroxysmal nocturnal hemoglobinuria (PNH) at the 12thCongress of European Hematology, organized by The EuropeanHematology Assoc...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

NYON, Switzerland, June 07, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today analysis of resultsdemonstrating that the Company's HIV vaccine elicited neutralizingIgA mucosal antibodies in a non-human primate model. Mucosal IgAantibodies are considered as a possible first line of defenseagainst infection by HIV. The data were presented by SylvainFleury, Ph.D., Mymetics'...

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that two posters were presented at the Endocrine Society's89th Annu...

Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients

CHICAGO, DARMSTADT, Germany, June 5, 2007 – Thisyear’s American Society of Clinical Oncology (ASCO) meetingin Chicago sees a wealth of promising new data presented regardingMerck KGaA’s targeted cancer therapy Erbitux®(cetuximab), further demonstrating the consistent efficacy andversatility of this agent in both first-line and subsequenttreatment of metastatic color...

NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien Tablets

FLEMINGTON, N.J.--(BUSINESS WIRE)--Jun 5, 2007 - NovaDel PharmaInc. (AMEX: NVD), a specialty pharmaceutical company developingoral spray formulations for a broad range of marketed treatments,today announced that its two clinical studies comparing zolpidemoral spray with zolpidem tablets have met their primarypharmacokinetic (PK), pharmacodynamic (PD) and safety objectives.Zolpidem tablets a...

Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA)today announced updated results from a joint analysis of two PhaseIII clinical trials studying Herceptin(R) (trastuzumab) for theadjuvant treatment of HER2-positive breast cancer. Data presentedat the 43rd Annual Meeting of the American Society of ClinicalOncology (ASCO) showed that, with median follow-up of nearly threeyears...

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

Company Launches 1,000-Patient Lung Cancer Diversity Study CHICAGO, June 01, 2007 /PRNewswire-FirstCall/ -- Statistics showlung cancer is the leading cause of cancer death inAfrican-Americans, with 21,550 new cases expected to be diagnosedand 16,700 deaths expected this year.(i) Equally devastating, lungcancer is the leading cause of cancer death in Hispanic men and thesecond leading caus...

Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds

STANFORD, Calif.--(BUSINESS WIRE)--May 24, 2007 - A new analysishas found that many alcohol treatment studies are designed in waysthat inadvertently omit women and African-Americans fromparticipation. The Stanford University School of Medicineresearcher who led the effort said the findings should remind allscientists that strict study eligibility criteria can haveunintended, negative conseq...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007

37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 TargetedAgent Studies INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall/ -- LillyOncology will unveil 76 studies at the 43rd Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) in Chicago, Ill. fromJune 1-5, 2007. The company will present important data onGEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexedf...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

AstraZeneca Focuses Research on Growing Childhood Condition WASHINGTON, May 22, 2007 /PRNewswire-FirstCall/ -- AstraZenecawill present several studies today regarding pediatric patientswith gastroesophageal reflux disease (GERD) during oral and postersessions at the annual Digestive Disease Week meeting held at theWashington Convention Center. The studies being presented further sup...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed NoSignificant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ --Findings from two separate pooled analyses - one examining theeffect of desvenlafaxine succinate on anxious symptoms and theother on painful symptoms associated with major depressive disorder(MDD) -- as well as a sep...

Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in Preclinical Studies

LUCCA, ITALY, ­ May 14, 2007-Acceleron Pharma, Inc., abiopharmaceutical company developing therapeutics for the treatmentof musculoskeletal, metabolic and cancer-related diseases, todayannounced results of a preclinical study with ACE-031 thatdemonstrated the ability of the compound to increase muscle massand strength in normal mice and in murine models of musculardystrophy. ACE-031...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results of a preclinical study withACE-031 that demonstrated the ability of the compound to increasemuscle mass and strength in normal mice and in murine models ofmuscular dystrophy...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. today announced plans to present the resultsfrom two bremelanotide Phase 2b studies of men with erectiledysfunction (ED). The presenters are Jed Kaminetsky, MD, ClinicalAssistant Professor, Department of Urology, NYU School of Medicine;Stanley E. Althof, PhD,...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- VitroStudies for Promising Alzheimer's Drug LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is pleased to announce positive results were attained with itslate-stage preclinical/nonclinical testing of Caprospinol (SP-233),with well recognized in-vitro models....

Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron

BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today the results of three clinicalstudies with Betaseron(R) (interferon beta-1b), presented this weekat the American Academy of Neurology's (AAN) 59th Annual Meeting,demonstrating early efficacy, long-term tolerability, and highpatient satisfaction with treatment in patients with relapsingforms of multiple sc...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

Labtec’s Next Generation Pain Patch Successful in Clinical Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld,Germany), a specialty pharmaceutics company announces positiveresults from a multiple dose clinical study for their proprietarySufentanil transdermal patch. “Today, we are pleased to announce the successfulcompletion of the second clinical trial for our SufentanilTDS®. Our goal for this program was to complete th...

Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgen's INGN 241

AUSTIN, Texas--(BUSINESS WIRE)--Apr 25, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) today announced the publication ofnew preclinical data describing how an intrinsic cell survivalpathway impacts the anticancer activity of INGN 241. Inhibition ofthis pathway, known as NF-kB, enhanced the tumor killing effects ofINGN 241 in cell culture and in preclinical models of human tumors.Researche...

Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease

Conference Call Begins Today at 11:00 a.m. Eastern Time LONDON, April 24, 2007 /PRNewswire-FirstCall/ -- AmarinCorporation plc ("Amarin" or the "Company") today announcestop-line results from its two Phase III clinical trials of Miraxionto treat Huntington's disease (HD). The Company conducted two PhaseIII double-blind, placebo-controlled studies in which HD patientswere randomized to rec...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by CombiningCytokines With Peregrine's Anti-PS Antibodies Demonstrate IncreasedAnti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of canc...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood VesselDensity and Serum PSA Levels in Prostate Tumors - LOS ANGELES and TUSTIN, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hepatitis Cvirus (HCV) infection, today announced that p...